Last updated on August 2019

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF..

Clinical Study Identifier: NCT02924727

Find a site near you

Start Over

Novartis Investigative Site

St Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

St. Petersburg, Russian Federation
1.2miles
  Connect »

Novartis Investigative Site

Saint-Petersburg, Russian Federation
2.61miles
  Connect »

Novartis Investigative Site

S.-Petersburg, Russian Federation
4.45miles
  Connect »

Novartis Investigative Site

Saint Petersburg, Russian Federation
5.69miles
  Connect »